Elanco Animal Health Incorporated (NYSE:ELAN) Stock Holdings Lowered by Black Creek Investment Management Inc.

Black Creek Investment Management Inc. lowered its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 11.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,914,446 shares of the company’s stock after selling 2,244,989 shares during the period. Elanco Animal Health comprises about 9.6% of Black Creek Investment Management Inc.’s investment portfolio, making the stock its 3rd biggest holding. Black Creek Investment Management Inc. owned approximately 3.63% of Elanco Animal Health worth $258,505,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. grew its position in shares of Elanco Animal Health by 22.2% in the 4th quarter. Victory Capital Management Inc. now owns 65,512 shares of the company’s stock worth $976,000 after buying an additional 11,910 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in Elanco Animal Health during the 4th quarter valued at $913,000. ING Groep NV bought a new position in Elanco Animal Health in the 4th quarter worth $1,062,000. Norges Bank bought a new position in Elanco Animal Health in the 4th quarter worth $62,510,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Elanco Animal Health in the 4th quarter worth about $1,991,000. Institutional investors own 97.48% of the company’s stock.

Insider Transactions at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons purchased 100,000 shares of Elanco Animal Health stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Harrington acquired 3,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, August 22nd. The stock was acquired at an average price of $14.85 per share, with a total value of $51,975.00. Following the completion of the acquisition, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The disclosure for this purchase can be found here. Insiders own 0.57% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $14.47 on Monday. Elanco Animal Health Incorporated has a 52 week low of $8.52 and a 52 week high of $18.80. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. The stock has a market cap of $7.15 billion, a P/E ratio of -5.46, a P/E/G ratio of 1.44 and a beta of 1.40. The business’s 50 day moving average price is $13.87 and its 200-day moving average price is $15.20.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The business had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Piper Sandler decreased their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, July 1st. Barclays decreased their target price on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.57.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.